Early results from clinical trials on substances like MDMA and psilocybin have been encouraging. In the middle of what is often regarded as a mental health crisis, many of these initiatives target a few of the most expensive and challenging mental health conditions while they are still happening. Researchers and executives discussed how that might convince health insurers, or “payors,” to jump on board during a Perspective on Psychedelics conference in New York.
Let’s be real: cannabis culture in 2026 looks nothing like it did even a decade…
A first-person review of the hemp-derived THC cocktail base I poured at our Cannabis Cup…
Every paper mill in the world still runs on the continuous-web design a Frenchman patented…
A new AI-assisted sci-fi satire from filmmaker Dan Levy Dagerman and the Space Weed Universe…
Spain has increased penalties for electricity theft linked to indoor cannabis cultivation after Endesa reported…
How a 52-year-old first-time grower turned trial and error into a show-stopping harvest The first…